COMPARISON OF METHODS TO CALCULATE CYCLOSPORINE-A BIOAVAILABILITY FROM CONSECUTIVE ORAL AND INTRAVENOUS DOSES

被引:21
作者
KARLSSON, MO
LINDBERGFREIJS, A
机构
[1] Department of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmacy, University of Uppsala, Uppsala, S-751 23
来源
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS | 1990年 / 18卷 / 04期
关键词
bioavailability estimation; cyclosporine A; pharmacokinetics; plasma; uremic patients;
D O I
10.1007/BF01062270
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics of cyclosporine A (CyA) was studied in 21 uremic patients. The plasma concentrations after an oral dose and a subsequent short-term infusion were analyzed simultaneously by nonlinear regression. Bi- and triexponential disposition models with either zero- or first-order absorption were fitted to the data. A triexponential disposition model with zero-order absorption was generally found to best describe the concentration-time profile. The bioavailability and clearance were estimated to be 0.24±0.10 and 21±8 L/hr, respectively. These values differed only marginally from those predicted by the other models. Similar bioavailability estimates were also obtained from a three-compartment model where elimination was assumed saturable, from a deconvolution procedure, and from analyses based on blood concentrations. Markedly higher bioavailabilities (0.34±0.13) were obtained when a model-independent AUC correction procedure, commonly used to calculate CyA bioavailability, was used. The difference could not be explained by poor description of data in the model-dependent analyses, but rather by overestimation in the model-independent analyses mainly due to errors in the extrapolations used. Thus, by the simultaneous fitting procedure, which is a new approach for estimating CyA bioavailability, drawbacks of the AUC correction procedure could be avoided. Further, future studies of CyA bioavailability could be designed with a markedly shorter and more convenient length of time if analyzed by the proposed method. © 1990 Plenum Publishing Corporation.
引用
收藏
页码:293 / 311
页数:19
相关论文
共 46 条
[1]  
ALBRECHT K, 1987, TRANSPLANT P, V19, P1719
[2]  
BEVERIDGE T, 1981, CURR THER RES CLIN E, V30, P5
[3]  
BOZKURT F, 1987, CLIN NEPHROL, V28, P10
[4]  
BURCKART G, 1985, TRANSPLANT P, V17, P1172
[5]   CYCLOSPORINE ABSORPTION FOLLOWING ORTHOTOPIC LIVER-TRANSPLANTATION [J].
BURCKART, GJ ;
VENKATARAMANAN, R ;
PTACHCINSKI, RJ ;
STARZL, TE ;
GARTNER, JC ;
ZITELLI, BJ ;
MALATACK, JJ ;
SHAW, BW ;
IWATSUKI, S ;
VANTHIEL, DH .
JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 26 (08) :647-651
[6]   PHYSIOLOGICAL AND PHARMACOLOGICAL VARIABILITY IN ESTIMATED HEPATIC BLOOD-FLOW IN MAN [J].
DANESHMEND, TK ;
JACKSON, L ;
ROBERTS, CJC .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 11 (05) :491-496
[7]   INTRAVENOUS CYCLOSPORINE KINETICS IN RENAL-FAILURE [J].
FOLLATH, F ;
WENK, M ;
VOZEH, S ;
THIEL, G ;
BRUNNER, F ;
LOERTSCHER, R ;
LEMAIRE, M ;
NUSSBAUMER, K ;
NIEDERBERGER, W ;
WOOD, A .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 34 (05) :638-643
[8]  
Gibaldi M., 1982, PHARMACOKINETICS, Vsecond
[9]   PHARMACOKINETICS OF ORAL CYCLOSPORINE-A (SANDIMMUN) IN HEALTHY-SUBJECTS [J].
GREVEL, J ;
NUESCH, E ;
ABISCH, E ;
KUTZ, K .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 31 (02) :211-216
[10]   ABSORPTION KINETICS OF CYCLOSPORINE IN HEALTHY-VOLUNTEERS [J].
GUPTA, SK ;
BENET, LZ .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1989, 10 (06) :591-596